Based on the observed pharmacophoric structural features for the reported dual COX/15-LOX inhibitors and inspired by the abundance of COX/LOX inhibitory activities reported for the 1,2,4-triazine and quinoline scaffolds, we designed and synthesized novel 1,2,4-triazine-quinoline hybrids (8a-n). The synthesized hybrids were evaluated in vitro as dual COXs/15-LOX inhibitors. The new triazine-quinoline hybrids (8a-n) exhibited potent COX-2 inhibitory profiles (IC<sub>50</sub> = 0.047-0.32 μM, SI ∼ 20.6-265.9) compared to celecoxib (IC<sub>50</sub> = 0.045 μM, SI ∼ 326). Moreover, they revealed potent inhibitory activities against 15-LOX enzyme compared to reference quercetin (IC<sub>50</sub> = 1.81-3.60 vs. 3.34 μM). Hybrid 8e was the most potent and selective dual COX-2/15-LOX inhibitor (COX-2 IC<sub>50</sub> = 0.047 μM, SI = 265.9, 15-LOX IC<sub>50</sub> = 1.81 μM). These hybrids were further challenged by their ability to inhibit NO, ROS, TNF-α, IL-6 inflammatory mediators, and 15-LOX product, 15-HETE, production in LPS-activated RAW 264.7 macrophages cells. Compound 8e was the most potent hybrid in reducing ROS and 15-HETE levels showing IC<sub>50</sub> values of 1.02 μM (11-fold more potent than that of celecoxib, IC<sub>50</sub> = 11.75 μM) and 0.17 μM (about 43 times more potent than celecoxib, IC<sub>50</sub> = 7.46 μM), respectively. Hybrid 8h exhibited an outstanding TNF-α inhibition with IC<sub>50</sub> value of 0.40 μM which was about 25 times more potent than that of celecoxib and diclofenac (IC<sub>50</sub> = 10.69 and 10.27 μM, respectively). Docking study of the synthesized hybrids into the active sites of COX-2 and 15-LOX enzymes ensures their favored binding affinity. To our knowledge, herein we reported the first 1,2,4-triazine-quinoline hybrids as dual COX/15-LOX inhibitors.